23:04 , Oct 26, 2018 |  BC Extra  |  Politics & Policy

FDA grants first qualification of a clinical safety biomarker

FDA qualified a group of kidney injury biomarkers from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC), marking the first...
20:30 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Guardant gets pop after IPO; Kodiak prices below range

Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) and ophthalmic company Kodiak Sciences Inc. (NASDAQ:KOD) each priced IPOs late Oct. 3. Guardant priced above its proposed range and posted a big gain on Thursday, while Kodiak...
14:06 , Oct 4, 2018 |  BC Extra  |  Financial News

Guardant gets pop after IPO; Kodiak prices below range

Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) and ophthalmic company Kodiak Sciences Inc. (NASDAQ:KOD) each priced IPOs late Wednesday. Guardant priced above its proposed range and posted a big gain on Thursday, while Kodiak priced...
22:44 , Sep 13, 2018 |  BC Week In Review  |  Financial News

Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform,...
02:07 , Sep 10, 2018 |  BC Extra  |  Financial News

With anti-VEGF challenger in clinic, Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform,...
06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates,...
16:36 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Celgene planning regulatory submissions for Revlimid in indolent lymphoma on Phase III win

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Rituxan in the Phase III AUGMENT trial to treat relapsed or refractory follicular and...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
18:35 , May 15, 2018 |  BC Innovations  |  Translation in Brief

Sustained delivery

Researchers from Vanderbilt University School of Medicine and Baylor College of Medicine have developed a new method for stable, long-term delivery of therapeutic proteins using antigen-specific T cells whose genomes have been modified with a...